Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASCO 2019
ASCO 2019
Did cancer clinical trials stay on track at ASCO 2019?
Pharmaforum
Fri, 07/19/19 - 01:00 pm
ASCO
clinical trials
cancer
ASCO 2019
bladder cancer
breast cancer
prostate cancer
pancreatic cancer
3 takeaways from cancer's biggest conference
Biopharma Dive
Thu, 06/6/19 - 10:03 pm
Amgen
KRAS
accelerated approvals
Turning Point Therapeutics
Keytruda
Opdivo
ASCO 2019
Was ASCO 2019 'quiet'? Pharma, biotech execs weigh in
Fierce Pharma
Wed, 06/5/19 - 07:34 pm
ASCO 2019
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
Wed, 06/5/19 - 10:43 am
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo
BioCentury
Wed, 06/5/19 - 12:12 am
ASCO 2019
NKTR-214
Nektar Therapeutics
metastatic melanoma
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
Tue, 06/4/19 - 12:18 pm
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Tue, 06/4/19 - 12:16 pm
Novartis
ASCO 2019
Incyte
MET inhibitors
capmatinib
non-small cell lung cancer
3 Cancer Stocks Given a Lift by Amgen
Motley Fool
Tue, 06/4/19 - 11:07 am
Amgen
KRAS
AMG 510
Mirati Therapeutics
Array Biopharma
Gilead Sciences
ASCO 2019
Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?
Investors Business Daily
Mon, 06/3/19 - 11:37 pm
Amgen
AMG 510
KRAS
ASCO 2019
lung cancer
colon cancer
ASCO 2019 – The results of clinical practices changing phase III studies
Pharmaforum
Mon, 06/3/19 - 11:32 pm
clinical trials
ASCO 2019
Merck
AstraZeneca
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
Mon, 06/3/19 - 08:17 pm
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
Gilead highlights Yescarta survival data in ASCO update
Pharmaforum
Mon, 06/3/19 - 07:46 pm
Gilead Sciences
clinical trials
Yescarta
relapsed or refractory diffuse large B-cell lymphoma
ASCO 2019
ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR
Fierce Biotech
Mon, 06/3/19 - 11:43 am
ASCO 2019
clinical trials
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
ASCO: With FDA review nearing, Epizyme shares updated sarcoma data
Fierce Biotech
Mon, 06/3/19 - 11:32 am
ASCO 2019
Epizyme
clinical trials
tazemetostat
epithelioid sarcoma
Early cancer drug data give Amgen hope it's 'cracked KRAS code'
Biopharma Dive
Mon, 06/3/19 - 11:30 am
ASCO 2019
KRAS
lung cancer
colorectal cancer
pancreatic cancer
Amgen
AMG 510
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Pharmaceutical Business Review
Mon, 06/3/19 - 11:29 am
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win
Fierce Pharma
Mon, 06/3/19 - 11:26 am
JNJ
Darzalex
ASCO 2019
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
BioCentury
Mon, 06/3/19 - 11:25 am
Blueprint Medicines
BLU-667
ASCO 2019
Eli Lilly
RET-altered cancer
LOXO-292
Seattle Genetics drug could provide new option for bladder cancer patients
Biopharma Dive
Mon, 06/3/19 - 11:24 am
Seattle Genetics
ASCO 2019
enfortumab vedotin
urothelial cancer
Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Fierce Biotech
Sun, 06/2/19 - 01:28 pm
ASCO 2019
Ayala Pharmaceuticals
Novartis
triple negative breast cancer
AL101
Pages
1
2
next ›
last »